November, single-dose vials of the popular weight-loss jab—Zepbound (tirzepatide)—will be available to buy from Walmart pharmacies across the U.S., thanks to a new collaboration between the retailer ...
During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...
Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...
MedPage Today on MSN
GI Risks Similar Among GLP-1 Drugs, but Higher Than With SGLT-2 Inhibitors
Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Walmart Pharmacies to offer weight-loss drug making obesity treatment more accessible for millions nationwide.
Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.
Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...
El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...
Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results